Sue Naim

563 total citations
8 papers, 299 citations indexed

About

Sue Naim is a scholar working on Molecular Biology, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sue Naim has authored 8 papers receiving a total of 299 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 5 papers in Hematology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sue Naim's work include Acute Myeloid Leukemia Research (5 papers), Histone Deacetylase Inhibitors Research (3 papers) and Epigenetics and DNA Methylation (3 papers). Sue Naim is often cited by papers focused on Acute Myeloid Leukemia Research (5 papers), Histone Deacetylase Inhibitors Research (3 papers) and Epigenetics and DNA Methylation (3 papers). Sue Naim collaborates with scholars based in United States, Canada and Belgium. Sue Naim's co-authors include Aram Oganesian, Yong Hao, Gail J. Roboz, Pietro Taverna, Mohammad Azab, Karen Yee, Wendy Stock, Naval Daver, Elias Jabbour and Raoul Tibes and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Sue Naim

8 papers receiving 298 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sue Naim United States 5 233 134 43 37 29 8 299
W.-K. Hofmann Germany 7 159 0.7× 120 0.9× 61 1.4× 34 0.9× 51 1.8× 9 268
Stephan Bohl Germany 8 176 0.8× 159 1.2× 56 1.3× 28 0.8× 24 0.8× 16 329
Nicole R. Grieselhuber United States 6 125 0.5× 89 0.7× 38 0.9× 46 1.2× 24 0.8× 22 202
Jean‐Valère Malfuson France 8 142 0.6× 143 1.1× 50 1.2× 21 0.6× 29 1.0× 15 250
Bert van der Reijden Netherlands 7 201 0.9× 182 1.4× 71 1.7× 33 0.9× 27 0.9× 13 314
Pekka Jaako Sweden 9 307 1.3× 98 0.7× 51 1.2× 16 0.4× 8 0.3× 16 389
Federica Cattina Italy 9 136 0.6× 187 1.4× 41 1.0× 44 1.2× 51 1.8× 35 282
Michael Grövdal Sweden 7 225 1.0× 243 1.8× 28 0.7× 28 0.8× 29 1.0× 13 323
Mariam Ibáñez Spain 9 245 1.1× 182 1.4× 49 1.1× 52 1.4× 46 1.6× 28 339
J. Maciejewski United States 7 180 0.8× 259 1.9× 30 0.7× 40 1.1× 24 0.8× 10 345

Countries citing papers authored by Sue Naim

Since Specialization
Citations

This map shows the geographic impact of Sue Naim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sue Naim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sue Naim more than expected).

Fields of papers citing papers by Sue Naim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sue Naim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sue Naim. The network helps show where Sue Naim may publish in the future.

Co-authorship network of co-authors of Sue Naim

This figure shows the co-authorship network connecting the top 25 collaborators of Sue Naim. A scholar is included among the top collaborators of Sue Naim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sue Naim. Sue Naim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Jahn, Nikolaus, Maral Saadati, Pierre Fenaux, et al.. (2023). Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients. Leukemia. 37(11). 2187–2196. 22 indexed citations
2.
Jahn, Nikolaus, Maral Saadati, Pierre Fenaux, et al.. (2023). P417: GENOMIC LANDSCAPE AND PROGNOSIS IN OLDER ACUTE MYELOID LEUKEMIA PATIENTS NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY. HemaSphere. 7(S3). e09006a7–e09006a7. 1 indexed citations
3.
Matei, Daniela, Sharad Ghamande, Lynda D. Roman, et al.. (2018). A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses. Clinical Cancer Research. 24(10). 2285–2293. 46 indexed citations
4.
Matulonis, Ursula A., Amit M. Oza, Angeles Alvarez Secord, et al.. (2016). Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study.. Journal of Clinical Oncology. 34(15_suppl). 5547–5547. 8 indexed citations
5.
Issa, Jean‐Pierre J., Gail J. Roboz, David A. Rizzieri, et al.. (2015). Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. The Lancet Oncology. 16(9). 1099–1110. 210 indexed citations
6.
Roboz, Gail J., Hagop M. Kantarjian, Patricia Kropf, et al.. (2015). Abstract CT321: First results of a 10-day regimen of SGI-110 (guadecitabine), a second generation hypomethylating agent (HMA) in previously untreated elderly AML who are not candidates for intensive chemotherapy. Cancer Research. 75(15_Supplement). CT321–CT321. 3 indexed citations
7.
Fleming, Gini F., Shekhar Ghamande, Yvonne G. Lin, et al.. (2014). Abstract 2320: Clinical epigenetic resensitization of platinum-resistant, recurrent ovarian cancer patients with SGI-110, a novel, second-generation, subcutaneously administered hypomethylating agent (HMA). Cancer Research. 74(19_Supplement). 2320–2320. 4 indexed citations
8.
Griffiths, Elizabeth A., Hagop M. Kantarjian, Gail J. Roboz, et al.. (2014). First results of a phase 2 study using a 10-day subcutaneous (SC) regimen of the novel hypomethylating agent (HMA) SGI-110 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML).. Journal of Clinical Oncology. 32(15_suppl). 7030–7030. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by W.-K. Hofmann Breakdown of academic impact, for papers by Stephan Bohl Breakdown of academic impact, for papers by Nicole R. Grieselhuber Breakdown of academic impact, for papers by Jean‐Valère Malfuson Breakdown of academic impact, for papers by Bert van der Reijden Breakdown of academic impact, for papers by Pekka Jaako Breakdown of academic impact, for papers by Federica Cattina Breakdown of academic impact, for papers by Michael Grövdal Breakdown of academic impact, for papers by Mariam Ibáñez Breakdown of academic impact, for papers by J. Maciejewski
Rankless by CCL
2026